MTOR and medulloblastoma: Against this background, we have previously shown that upstream of mTOR/AKT the clinically available PI3K inhibitor GDC‐0941 potently inhibits AKT phosphorylation in high‐risk variants of medulloblastoma and promotes survival in an orthotopic xenograft model 31.